Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoVector Hires Vice President of R&D for Nanotechnology Cancer Therapeutics

Abstract:
Dr. Paul M. Steed to Head IND Enabling Studies For Next Generation Targeted Cancer Drug

NanoVector Hires Vice President of R&D for Nanotechnology Cancer Therapeutics

RALEIGH, NC | Posted on January 14th, 2009

NanoVector, Inc. announced today that Paul M. Steed, Ph.D. has joined the company as its Vice President of Research and Development. Dr. Steed has 16 years of experience in pharmaceutical R & D, including 10 at Ciba/Novartis and 6 in the biotech industry. He has a thorough understanding of all aspects of pharmaceutical R&D, primarily in the areas of oncology and inflammation/immunology and has numerous high-impact publications. Most recently Dr. Steed served as head of biology for Serenex, which was acquired in April of 2008 by Pfizer, Inc; primarily for its oncology products in clinical and pre-clinical development. At Serenex Dr. Steed managed all aspects of biological research and preclinical biology and helped guide the lead cancer drug SNX-5422 through early development. His background spans small molecules and biologics, a unique combination essential for efficient progress of the NanoVector technology.

"We are delighted to have the opportunity to add someone of Dr. Steed's background to our senior management team," said Albert Bender, Ph.D. CEO. "Leveraging his extensive oncology development experience and leadership, Dr. Steed will accelerate our lead drug time to IND." Dr. Steed added, "I am excited to lead the effort to bring the NanoVector technology to fruition because it clearly can be a breakaway advancement in the treatment of cancer and potentially many other diseases."

####

About NanoVector, Inc.
NanoVector Inc. is commercializing the first biologic-based nanoparticle drug delivery system for the $48B/yr global cancer therapeutics market. Our breakaway technology overcomes all of the hurdles that have impeded chemistry-based nanocarrier systems and is capable of delivering selective targeting of tumors along with the precise intracellular delivery of anti-cancer agents for improved efficacy and fewer unpleasant side effects. The NanoVector technology is based upon a ubiquitous plant virus that has evolved for millions of years to have these ideal drug delivery characteristics, along with the ability to be exposed to mammals (including humans) in a completely benign fashion. To limit uptake to diseased cells, NanoVector has intelligently engineered the surface of the nanocarrier with targeting technology that specifically and exclusively targets tumor cells and the cell components relevant for the treatment/cargo. This technology transcends the long-standing drug paradigm for treating diseases.

For more information, please click here

Contacts:
NanoVector, Inc.
Albert Bender, Ph.D., CEO
919-878-8464

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Iranian Researchers Synthesize Stable Ceramic Nanopowders at Room Temperature September 20th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanomedicine

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

New non-invasive technique could revolutionize the imaging of metastatic cancer September 17th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Synthesis of Nanostructures with Controlled Shape, Size in Iran September 22nd, 2014

Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Jeff Andreson to Join Nanometrics as Chief Financial Officer September 4th, 2014

New Vice President Takes Helm at CNSE CMOST: Catherine Gilbert To Lead CNSE Children’s Museum of Science and Technology Through Expansion And Relocation August 29th, 2014

Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014

California Nanotechnologies Appoints Dr. Enrique Lavernia to the Board August 6th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE